Name

SERVIER LABORATORIES

Legal name

Công Ty TNHH Servier (Việt Nam)

Website

https://servier.vn

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical products
• Cardiovascular medicine
• Oncology therapeutics
• Diabetes treatments
• Venous disease therapies

Headquarters

HQ city

Ho Chi Minh City

HQ country

Vietnam

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Servier generates revenue primarily through the sale of prescription pharmaceutical products across its therapeutic areas: cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases (chronic venous disease, hemorrhoids), immune-inflammatory diseases, and neuroscience. Servier is a non-profit foundation-governed company that reinvests all net revenue into R&D.
2. Technology Transfer and Manufacturing: Servier generates revenue through technology transfer arrangements with local Vietnamese partners, such as the Ampharco partnership, where local manufacturers produce Servier's originator drugs for the Vietnamese market under licensing and technology transfer agreements.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Servier Laboratories develops, manufactures, and markets prescription pharmaceutical products across cardiovascular-metabolic diseases (hypertension, diabetes, angina), venous diseases, immune-inflammatory diseases, neuroscience, and oncology therapeutic areas in Vietnam. The company also offers digital health solutions including the MyServier HCP platform, the Elfie blood pressure monitoring app, and the Ngày Đầu Tiên early diagnosis program serving over 3 million Vietnamese patients annually.

Product overview

Servier Laboratories is an independent French pharmaceutical company governed by a non-profit foundation, operating in Vietnam since 1993. Its product portfolio centers on four core therapeutic areas: cardiovascular-metabolic therapies (covering hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases), immune-inflammatory therapies (lupus, scleroderma, Sjögren's syndrome), neuroscience (Parkinson's, autism), and oncology. Servier Vietnam serves over 3 million Vietnamese patients annually and operates several patient-facing digital tools: MyServier (a dedicated platform for healthcare professionals providing clinical content), the Elfie app (supporting patient treatment adherence and blood pressure monitoring), and the Ngày Đầu Tiên (First Day) project (a patient early-diagnosis and disease-management initiative). The company also pursues technology transfer partnerships such as the Ampharco arrangement to manufacture originator products domestically.

Differentiator

Problem solved

Functional benefit

Brands

• MyServier: Exclusive platform for healthcare professionals in Vietnam with in-depth content on therapeutic areas and product information
• Elfie
• Ngày Đầu Tiên (First Day)

Products and services

• MyServier HCP Portal A dedicated online platform for healthcare professionals working in Vietnam, providing in-depth clinical content in areas of coronary artery disease, venous disease, diabetes, and hypertension, as well as information on Servier Vietnam's products.
• Elfie Mobile App A mobile application that helps patients improve treatment adherence, and track and control blood pressure.
• Ngày Đầu Tiên (First Day) Project A program designed to help patients with hypertension, diabetes, and angina receive early diagnosis and better disease management.
• Cardiovascular-Metabolic Therapies Servier's core therapeutic area covering cardiovascular diseases with fixed-dose combination products (SPC) designed to simplify treatment and improve patient adherence. This includes treatments for hypertension, diabetes, cardiology, chronic venous, and hemorrhoidal diseases.
• Immune-Inflammatory Therapies Servier's therapeutic area focusing on immune-inflammatory diseases with R&D efforts concentrated on three autoimmune conditions with high unmet medical needs: systemic lupus erythematosus, scleroderma, and Sjögren's syndrome.
• Neuroscience Therapies Servier's therapeutic area focusing on neurodegenerative diseases and protein pathologies characterized by abnormal protein accumulation, including Parkinson's disease and rare diseases such as unilateral muscle atrophy sclerosis. Servier is collaborating with Neurochlore on Phase III studies for autism spectrum disorder.
• Oncology Therapies Servier's therapeutic area covering cancer treatment development, representing 25% of global turnover and 70% of R&D investments.

Quantifiable outcome

• Over 3 million Vietnamese patients treated annually with Servier drugs
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• AmpharcoflagshipStrategic or Co-development Partner · 27 May 2025Servier and Ampharco entered a technology transfer agreement for the local production of Servier's originator drugs in Vietnam. The partnership began in 2019, with Ampharco's plant completed in 2022 and EU-GMP certification achieved in 2025. When fully deployed, Ampharco will produce half of Servier's total originator drug volume for Vietnam. The agreement was signed at the French Embassy in Hanoi on May 27, 2025, witnessed by the French Minister of Economy and Vietnamese government officials. This aligns with Vietnam's goal to produce 100 originators domestically and 80% of medicines locally by 2045.
• Youmed VietnamcoreStrategic or Co-development Partner · 8 April 2025Servier Vietnam partners with Youmed (Công Ty TNHH YouMed Việt Nam) as a data controller for the NDT Nurse Program. Youmed provides the Y360 online learning platform for the program, manages user accounts for nurse participants, and delivers program communications. This program provides CME-certified training for nurses in Vietnam.
• Hanoi Medical University (Đại học Y Hà Nội)coreStrategic or Co-development Partner · 8 April 2025Hanoi Medical University collaborates with Servier Vietnam as a data controller for the NDT Nurse Program, providing Zoom-based online training sessions and CME certification for participating nurses. This partnership supports advanced nursing education and professional development in Vietnam.
• Bảo Yên District Communities (Lào Cai Province)minorOthers · 24 November 2024Servier Vietnam's 'Nowadays' team organized the 'Hướng về Bảo Yên thân thương' program, delivering disaster relief to communities affected by Typhoon Yagi in Lào Cai province. The company donated nearly 3 tons of rice and essential supplies to over 90 households and organized tree planting for environmental recovery in Xuân Thượng and Xuân Hòa communes.
• Enfants d'AsieminorOthers · 1 January 2019Since September 2019, Servier Vietnam has partnered with Enfants d'Asie on three programs: supporting highland youth studying at universities in HCMC, partnering with the HCMC Women's Charity Association (WOCA) to support 50 underprivileged students in primary and secondary school, and collaborating with Maison d'Amour religious congregation to support 90 children in suburban HCMC.
• Grow GreenminorOthers · 1 January 2019Since January 2019, Grow Green is an environmental initiative by Servier Vietnam with the mission of changing perceptions about environmental challenges, raising awareness about plastic pollution, and providing tools for behavioral change with a positive impact on the environment.
• Helen Keller International / Helen Keller VietnamminorStrategic or Co-development Partner · 1 January 2018Servier Vietnam participates in the ChildSight program, a vision screening and treatment initiative for children and teachers in underserved provinces of Vietnam, in partnership with Helen Keller International and Helen Keller Vietnam.
• LP4Y (Life Project 4 Youth)minorOthers · 1 January 2017From April 2017 to June 2020, Servier Vietnam supported LP4Y, a program helping disadvantaged Vietnamese youth aged 17–24 who had dropped out of school, by sharing knowledge, skills, and practical experience to help them approach their dreams and improve their employment prospects.
• Vietnam Cardiology Society (Hội Tim mạch học Việt Nam)coreStrategic or Co-development Partner · 1 January 2015The Vietnam Cardiology Society co-sponsors the 'Ngày Đầu Tiên' (First Day) project, an early diagnosis and disease management initiative for hypertension, diabetes, and angina patients. This project has been operating since 2015 and is officially recognized by the Ministry of Health of Vietnam.
• Vietnam Diabetes & Endocrinology Association (Hội Nội tiết & Đái tháo đường Việt Nam)coreStrategic or Co-development Partner · 1 January 2015The Vietnam Diabetes & Endocrinology Association co-sponsors the 'Ngày Đầu Tiên' (First Day) project alongside the Vietnam Cardiology Society and Servier Vietnam, contributing to early diagnosis and better disease control for diabetes and hypertension patients in Vietnam since 2015.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Roche Vietnam: Global pharmaceutical leader with a dominant oncology portfolio entering Vietnam; competes with Servier's expanding oncology ambitions and shares the multinational HCP engagement model.
• MSD (Merck) Vietnam: Multinational pharmaceutical company with strong diabetes, oncology, and vaccine franchises in Vietnam; competes with Servier in cardio-metabolic care and shares a similar multinational HCP-engagement playbook.
• Sanofi Vietnam: French-headquartered multinational pharmaceutical company with a strong Vietnam presence across cardiovascular, diabetes, and specialty therapeutics; competes directly with Servier Vietnam for HCP relationships and chronic-disease market share.
• Bayer Vietnam: German multinational with a significant cardiovascular and cardiometabolic portfolio in Vietnam; directly overlaps with Servier's hypertension and chronic-disease therapeutic focus.
• Takeda Pharmaceuticals Vietnam: Japanese-headquartered multinational with a presence across specialty, oncology, and rare disease therapeutics in Vietnam; competes for HCP mindshare and specialty-pharma positioning alongside Servier.
• AstraZeneca Vietnam: Global biopharmaceutical company with major cardiovascular and oncology franchises in Vietnam; competes with Servier in cardiology and increasingly in oncology where Servier is reallocating R&D.
• Novartis Vietnam: Swiss-headquartered multinational with strong cardiovascular and specialty care presence in Vietnam; competes with Servier in hypertension, heart failure, and chronic disease management.
• Pfizer Vietnam: One of the largest multinational pharmaceutical companies in Vietnam with broad cardiovascular, oncology, and specialty portfolios; competes for the same top-10 MNC ranking and HCP access that Servier holds.
• Boehringer Ingelheim Vietnam: Germany-based multinational with a leading cardiometabolic and respiratory franchise, including diabetes and stroke prevention; closely competes with Servier's diabetes and cardiovascular offerings in Vietnam.

Regional players

• DHG Pharmaceutical Joint Stock Company: One of the largest domestic Vietnamese pharmaceutical manufacturers; competes with Servier in cardiovascular and diabetes generics and is a likely local partner/competitor in the government's drive for domestic originator production.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/serviernavigateyourfuture
• LinkedInlinkedin.com/company/servier-vietnam

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SERVIER LABORATORIES